(Q26779042)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

"Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Case-control study of factors that trigger inflammatory bowel disease flares

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Cost effectiveness of treatments for inflammatory bowel disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

The challenge of compliance and persistence: focus on ulcerative colitis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Systematic review: adherence issues in the treatment of ulcerative colitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Glucocorticoid resistance in inflammatory bowel disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

The burden of inflammatory bowel disease on health care utilization and quality of life.

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3897-0

Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Evaluation of oral budesonide in the treatment of active distal ulcerative colitis

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729806

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study

28 November 2018

1 reference

12 December 2020

Binding kinetics of budesonide to the human glucocorticoid receptor

1 reference

12 December 2020

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

12 December 2020

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group

1 reference

12 December 2020

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

1 reference

12 December 2020

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

12 December 2020

Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis

1 reference

12 December 2020

A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies

1 reference

12 December 2020

1 reference

12 December 2020

Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver

1 reference

12 December 2020

Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid

1 reference

12 December 2020

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

1 reference

12 December 2020

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

12 December 2020

Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease

1 reference

12 December 2020

Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study

1 reference

12 December 2020

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

12 December 2020